SCHEMBL16800397

SCHEMBL16800397

CC/C=C/C/C=C/C/C=C/C/C=C/C/C=C/CCCC(=O)Oc1ccccc1C(=O)O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.67
KMT2A Q03164 3/20 0.67
MEN1 O00255 2/20 0.67
RECQL P46063 2/20 0.67
PTGS2 P35354 3/20 0.52
ADORA3 P0DMS8 2/20 0.52
NR1I2 O75469 2/20 0.52
PGR P06401 1/20 0.52
PDE4D Q08499 1/20 0.52
ALDH1A1 P00352 8/20 0.50
CYP19A1 P11511 4/20 0.50
PPARG P37231 4/20 0.50
PTGS1 P23219 3/20 0.50
EPHX2 P34913 3/20 0.50
F7 P08709 3/20 0.50
F3 P13726 3/20 0.50
OXER1 Q8TDS5 3/20 0.50
PPARD Q03181 2/20 0.50
PPARA Q07869 2/20 0.50
RXRA P19793 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5941119 1.00 KDM4E (0.67) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL16800400 0.95 KDM4E (0.64) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL16770315 0.95 KDM4E (0.64) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL17369040 0.95 KDM4E (0.64) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL455959 0.92 KDM4E (0.62) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL455960 0.92 KDM4E (0.62) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL469589 0.92 KDM4E (0.62) KDM4EKMT2AMEN1RECQLPTGS2
SCHEMBL16800410 0.91 KDM4E (0.73) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL8814970 0.91 KDM4E (0.73) KDM4EKMT2AMEN1RECQLALDH1A1
SCHEMBL8814964 0.91 KDM4E (0.73) KDM4EKMT2AMEN1RECQLALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150374839-A1 NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES KEAN UNIVERSITY (US) 2015-12-31 US disclosed
US-20150374839-A1 NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES KEAN UNIVERSITY (US) 2015-12-31 US disclosed
US-9056139-B2 Fatty acid-salicylate conjugates with enhanced therapeutic properties KEAN UNIVERSITY (US) 2015-06-16 US disclosed
US-9056139-B2 Fatty acid-salicylate conjugates with enhanced therapeutic properties KEAN UNIVERSITY (US) 2015-06-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150374839-A1 NOVEL FATTY ACID-SALICYLATE CONJUGATES WITH ENHANCED THERAPEUTIC PROPERTIES FASN, ELOVL1, ELOVL3 KDM4E 2152/4885KMT2A 2301/4885MEN1 4457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.